Research programme: proteasome inhibitors - QLi5 Therapeutics
Latest Information Update: 27 May 2022
At a glance
- Originator The Lead Discovery Center
- Developer QLi5 Therapeutics
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Research Autoimmune disorders; Inflammation